Reference
·Supporting source
Thailand AI drug discovery and pharma biotech AI-tooling revenue (2024-2028)
THB 14-24B (2027E)
Thailand's addressable AI drug discovery and pharma biotech AI-tooling revenue pool tracks from roughly THB 1.9 billion in 2024 to an estimated THB 14-24 billion mid-case at 2027, a 10x expansion over three years. Inflection drivers are the NSTDA BIOTEC AI Drug Discovery Centre commissioning, BOI Section 8 R&D tax incentives effective Q1 2026, the TFDA accelerated approval pathway targeted Q3 2026, foreign-partner Thailand MOUs (Insilico, Atomwise, Exscientia, Iktos, BenevolentAI) signed 2025-2026, and Genome Thailand 50K WGS cohort data dropping incrementally from 2026 onward. Local manufacturing scale-up via GPO and Siam Bioscience adds an additional THB 8-22 billion incremental revenue not counted in the discovery and tooling pool.
Figure in context
Thailand's addressable AI drug discovery and pharma biotech AI-tooling revenue pool tracks from roughly THB 1.9 billion in 2024 to an estimated THB 14-24 billion mid-case at 2027, a 10x expansion over three years. Inflection drivers are the NSTDA BIOTEC AI Drug Discovery Centre commissioning, BOI Section 8 R&D tax incentives effective Q1 2026, the TFDA accelerated approval pathway targeted Q3 2026, foreign-partner Thailand MOUs (Insilico, Atomwise, Exscientia, Iktos, BenevolentAI) signed 2025-2026, and Genome Thailand 50K WGS cohort data dropping incrementally from 2026 onward. Local manufacturing scale-up via GPO and Siam Bioscience adds an additional THB 8-22 billion incremental revenue not counted in the discovery and tooling pool.
Interpretation notes
What this tells you
Thailand's addressable AI drug discovery and pharma biotech AI-tooling revenue pool tracks from roughly THB 1.9 billion in 2024 to an estimated THB 14-24 billion mid-case at 2027, a 10x expansion over three years. Inflection drivers are the NSTDA BIOTEC AI Drug Discovery Centre commissioning, BOI Section 8 R&D tax incentives effective Q1 2026, the TFDA accelerated approval pathway targeted Q3 2026, foreign-partner Thailand MOUs (Insilico, Atomwise, Exscientia, Iktos, BenevolentAI) signed 2025-2026, and Genome Thailand 50K WGS cohort data dropping incrementally from 2026 onward. Local manufacturing scale-up via GPO and Siam Bioscience adds an additional THB 8-22 billion incremental revenue not counted in the discovery and tooling pool.
What not to do with it
Values in THB billion. 2027 mid-point THB 18.5B sits inside the THB 14-24B band; 2028 projection assumes TFDA accelerated pathway clears its first AI-discovered compound and foreign-pharma cohort spend doubles on AstraZeneca, Roche, Pfizer, Novartis, Eli Lilly expansion programmes.
Related figures
Adjacent numbers that add context without drowning the value.
Thailand AI drug discovery activity mix (2027 estimate)
NSTDA BIOTEC; Siriraj Centre of Research Excellence; SCB EIC pharma outlook; PReMA industry profile
Genome Thailand WGS cohort buildout (2024-2027)
Ministry of Higher Education, Science, Research and Innovation; NSTDA Genome Thailand programme; NSTDA annual report
Thailand AI drug discovery operator concentration (2027 estimate)
NSTDA BIOTEC; Mahidol Centre for Computational Drug Discovery; Chulalongkorn Health Innovation Hub; Siriraj Centre of Research Excellence; foreign-partner disclosures
BOI Section 8 AI compute credit (effective Q1 2026)
Thailand Board of Investment Section 8 R&D announcement
Foreign-pharma Thailand clinical-trial spend (2025-2027)
AstraZeneca Thailand R&D briefings; Roche Thailand personalised healthcare disclosures; SCB EIC pharma outlook
Thailand AI drug discovery cost-per-validated-target (2026)
NSTDA BIOTEC; Mahidol Centre for Computational Drug Discovery; SCB EIC pharma outlook
Report context
Atlas actors in this figure's reports
Profiles covered in the report that cite this number.